Prediction of clinical response to antidepressants in patients with depression: neurophysiology in clinical practice. 2007

Oliver Pogarell, and Georg Juckel, and Christine Norra, and Gregor Leicht, and Susanne Karch, and Nadine Schaaff, and Malte Folkerts, and Ahmad Ibrahim, and Christoph Mulert, and Ulrich Hegerl
Department of Psychiatry, Ludwig-Maximilians-University, Munich, Germany. oliver.pogarell@med.uni-muenchen.de

Brain monoaminergic neurotransmission is involved in the pathophysiology of various psychiatric disorders including depression. Reliable indicators of central monoaminergic activity might be helpful to specifically identify and differentiate dysfunctions in individual patients in order to selectively adjust medication and predict clinical response. In patients with depression, predictors of treatment response to serotonergic versus non-serotonergic (e.g., noradrenergic) antidepressants could be of considerable clinical relevance by avoiding unfavorable factors such as a prolonged duration of the disorder, risk of suicidality and therapy-resistance. Consequently, these tools might help to decrease direct and indirect costs of treatment. The loudness dependence of the N1/P2 component of auditory evoked potentials (LD) has been proposed as a noninvasive neurophysiological indicator of central serotonergic function. This review focuses on recent studies providing evidence for the validity of LD as an indirect serotonergic marker and highlights data on the clinical application in terms of prediction of treatment response in patients with depression.

UI MeSH Term Description Entries
D009482 Neurophysiology The scientific discipline concerned with the physiology of the nervous system.
D010818 Practice Patterns, Physicians' Patterns of practice related to diagnosis and treatment as especially influenced by cost of the service requested and provided. Clinical Practice Patterns,Physician's Practice Patterns,Clinical Practice Pattern,Pattern, Clinical Practice,Patterns, Clinical Practice,Practice Pattern, Clinical,Practice Patterns, Clinical,Practice Patterns, Physician's,Prescribing Patterns, Physician,Physician Practice Patterns,Physician Prescribing Pattern,Physician Prescribing Patterns,Physician's Practice Pattern,Physicians' Practice Pattern,Physicians' Practice Patterns,Practice Pattern, Physician's,Practice Pattern, Physicians',Practice Patterns, Physician,Prescribing Pattern, Physician
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D003863 Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders. Depressive Symptoms,Emotional Depression,Depression, Emotional,Depressive Symptom,Symptom, Depressive
D004569 Electroencephalography Recording of electric currents developed in the brain by means of electrodes applied to the scalp, to the surface of the brain, or placed within the substance of the brain. EEG,Electroencephalogram,Electroencephalograms
D005072 Evoked Potentials, Auditory The electric response evoked in the CEREBRAL CORTEX by ACOUSTIC STIMULATION or stimulation of the AUDITORY PATHWAYS. Auditory Evoked Potentials,Auditory Evoked Response,Auditory Evoked Potential,Auditory Evoked Responses,Evoked Potential, Auditory,Evoked Response, Auditory,Evoked Responses, Auditory,Potentials, Auditory Evoked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000161 Acoustic Stimulation Use of sound to elicit a response in the nervous system. Auditory Stimulation,Stimulation, Acoustic,Stimulation, Auditory
D000928 Antidepressive Agents Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. Antidepressant,Antidepressant Drug,Antidepressant Medication,Antidepressants,Antidepressive Agent,Thymoanaleptic,Thymoanaleptics,Thymoleptic,Thymoleptics,Antidepressant Drugs,Agent, Antidepressive,Drug, Antidepressant,Medication, Antidepressant
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Oliver Pogarell, and Georg Juckel, and Christine Norra, and Gregor Leicht, and Susanne Karch, and Nadine Schaaff, and Malte Folkerts, and Ahmad Ibrahim, and Christoph Mulert, and Ulrich Hegerl
January 1986, Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952),
Oliver Pogarell, and Georg Juckel, and Christine Norra, and Gregor Leicht, and Susanne Karch, and Nadine Schaaff, and Malte Folkerts, and Ahmad Ibrahim, and Christoph Mulert, and Ulrich Hegerl
January 1999, Journal of affective disorders,
Oliver Pogarell, and Georg Juckel, and Christine Norra, and Gregor Leicht, and Susanne Karch, and Nadine Schaaff, and Malte Folkerts, and Ahmad Ibrahim, and Christoph Mulert, and Ulrich Hegerl
July 2004, Mymensingh medical journal : MMJ,
Oliver Pogarell, and Georg Juckel, and Christine Norra, and Gregor Leicht, and Susanne Karch, and Nadine Schaaff, and Malte Folkerts, and Ahmad Ibrahim, and Christoph Mulert, and Ulrich Hegerl
May 1990, The American journal of psychiatry,
Oliver Pogarell, and Georg Juckel, and Christine Norra, and Gregor Leicht, and Susanne Karch, and Nadine Schaaff, and Malte Folkerts, and Ahmad Ibrahim, and Christoph Mulert, and Ulrich Hegerl
June 1987, Biological psychiatry,
Oliver Pogarell, and Georg Juckel, and Christine Norra, and Gregor Leicht, and Susanne Karch, and Nadine Schaaff, and Malte Folkerts, and Ahmad Ibrahim, and Christoph Mulert, and Ulrich Hegerl
June 1988, British journal of hospital medicine,
Oliver Pogarell, and Georg Juckel, and Christine Norra, and Gregor Leicht, and Susanne Karch, and Nadine Schaaff, and Malte Folkerts, and Ahmad Ibrahim, and Christoph Mulert, and Ulrich Hegerl
February 2016, Biological psychiatry,
Oliver Pogarell, and Georg Juckel, and Christine Norra, and Gregor Leicht, and Susanne Karch, and Nadine Schaaff, and Malte Folkerts, and Ahmad Ibrahim, and Christoph Mulert, and Ulrich Hegerl
January 2016, Clinical neurophysiology practice,
Oliver Pogarell, and Georg Juckel, and Christine Norra, and Gregor Leicht, and Susanne Karch, and Nadine Schaaff, and Malte Folkerts, and Ahmad Ibrahim, and Christoph Mulert, and Ulrich Hegerl
February 2010, The international journal of neuropsychopharmacology,
Oliver Pogarell, and Georg Juckel, and Christine Norra, and Gregor Leicht, and Susanne Karch, and Nadine Schaaff, and Malte Folkerts, and Ahmad Ibrahim, and Christoph Mulert, and Ulrich Hegerl
January 2004, The Journal of clinical psychiatry,
Copied contents to your clipboard!